Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors

被引：5
|
作者：
Duran, I.
Hotte, S.
Chen, E.
Hirte, H.
MacLean, M.
Turner, S.
Pond, G.
Wright, J.
Dancey, J.
Siul, L.
机构：
[1] Princess Margaret Hosp Phase II Consortium, Toronto, ON, Canada
[2] Natl Canc Inst, Bethesda, MD USA
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70555-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
550
引用
收藏
页码：167 / 167
页数：1
相关论文
共 50 条
  • [11] Phase I pharmacodynamic (PD) and pharmacokinetic (PIK) analysis of the sorafenib (S) and erlotinib (E) combination in patients with advanced solid tumors
    Le Tourneau, C.
    Duran, I.
    Chen, E.
    Wang, L.
    Tsao, M.
    Hedley, D.
    Phan, N.
    Do, T.
    Metser, U.
    Siu, L.
    EJC SUPPLEMENTS, 2008, 6 (12): : 129 - 129
  • [12] Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors.
    Westin, Shannon Neville
    Smart, Melody L.
    Pal, Navdeep
    Urbauer, Diana L.
    Janku, Filip
    Wheler, Jennifer J.
    Piha-Paul, Sarina Anne
    Naing, Aung
    Tsimberidou, Apostolia Maria
    Fu, Siqing
    Falchook, Gerald Steven
    Hong, David S.
    Zinner, Ralph
    Subbiah, Vivek
    Culotta, Kirk Salvatore
    Lu, Karen H.
    Coleman, Robert L.
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [13] Dual inhibition of the epidermal growth factor receptor (EGFR) pathway with the combination of cetuximab and erlotinib: A phase I study in patients with advanced solid malignancies
    Guarino, Michael J.
    Schneider, Charles J.
    Hosford, Martha A.
    Brahmer, Julie R.
    Rudin, Charles M.
    Finckenstein, Friedrich Graf
    Philip-Norton, Robyn E.
    Lu, Haolan
    Weber, Martin R.
    Ettinger, David S.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3383S - 3383S
  • [14] Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
    Puzanov, Igor
    Sosman, Jeffrey
    Santoro, Armando
    Saif, Muhammad W.
    Goff, Laura
    Dy, Grace K.
    Zucali, Paolo
    Means-Powell, Julie A.
    Ma, Wen Wee
    Simonelli, Matteo
    Martell, Robert
    Chai, Feng
    Lamar, Maria
    Savage, Ronald E.
    Schwartz, Brian
    Adjei, Alex A.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (01) : 159 - 168
  • [15] Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
    Igor Puzanov
    Jeffrey Sosman
    Armando Santoro
    Muhammad W. Saif
    Laura Goff
    Grace K. Dy
    Paolo Zucali
    Julie A. Means-Powell
    Wen Wee Ma
    Matteo Simonelli
    Robert Martell
    Feng Chai
    Maria Lamar
    Ronald E. Savage
    Brian Schwartz
    Alex A. Adjei
    Investigational New Drugs, 2015, 33 : 159 - 168
  • [16] A phase I dose escalation study with sorafenib (Sor) in combination with sirolimus (Sir) in patients (pts) with solid tumors
    van Herpen, C.
    Desar, I. M. E.
    Verijdt, R.
    van der Graaf, W. T. A.
    Timmer-Bonte, J. N. H.
    EJC SUPPLEMENTS, 2009, 7 (02): : 130 - 130
  • [17] A phase I trial of riluzole and sorafenib in patients with advanced solid tumors and melanoma.
    Mehnert, Janice M.
    Semlani, Neha
    Wen, Yvonne
    Tan, Antoinette R.
    Moss, Rebecca Anne
    Adams, Shari
    Stein, Mark N.
    Ross, Mikel
    Kane, Michael P.
    Gibbon, Darlene
    Wright, John Joseph
    Aisner, Joseph
    Chen, Suzie
    Goydos, James S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [18] Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors
    Romain Varnier
    Alicja Puszkiel
    Michel Tod
    Sara Calattini
    Lea Payen
    Jonathan Lopez
    Jérome Guitton
    Vérane Schwiertz
    Juliette Fontaine
    Julien Peron
    Denis Maillet
    Sophie Tartas
    Nathalie Bonnin
    Olivier Colomban
    Diane Augu-Denechere
    Gilles Freyer
    Benoit You
    Cancer Chemotherapy and Pharmacology, 2023, 91 : 361 - 373
  • [19] Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors
    Varnier, Romain
    Puszkiel, Alicja
    Tod, Michel
    Calattini, Sara
    Payen, Lea
    Lopez, Jonathan
    Guitton, Jerome
    Schwiertz, Verane
    Fontaine, Juliette
    Peron, Julien
    Maillet, Denis
    Tartas, Sophie
    Bonnin, Nathalie
    Colomban, Olivier
    Augu-Denechere, Diane
    Freyer, Gilles
    You, Benoit
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (05) : 361 - 373
  • [20] Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer
    Siu, LL
    Awada, A
    Takimoto, CH
    Piccart, M
    Schwartz, B
    Giannaris, T
    Lathia, C
    Petrenciuc, O
    Moore, MJ
    CLINICAL CANCER RESEARCH, 2006, 12 (01) : 144 - 151
12345